Cetero Research Announces More Than 500 Diabetes Studies Completed
Cetero Research announced it has completed more than 500 diabetes research studies in the past three years for both Type 1 and Type 2 diabetics, including complex clamp studies and studies in Phase I, II, III and IV. Cetero combines both pivotal pharmacokinetic studies and proof-of-concept studies in one study.
“Approximately eight percent of the U.S. population struggles with diabetes, and the numbers continue to grow,” said Dr. Troy McCall, CEO of Cetero Research. “According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are a record number of diabetes drugs in development to help the 20 million Americans battling this disease every day. We want to help get those treatments through proof-of-concept faster by providing a full range of services to pharmaceutical companies.”
Cetero runs first-in-human, pharmacokinetic, and proof-of concept studies in diabetics across three of its clinical facilities.
In one diabetes study for a global pharmaceutical company, Cetero randomized the first subject about three weeks after screening began. The final one of the 56 subjects was randomized 13 weeks after the first screening.
Cetero maintains recruiting strategies to build their database of potential study participants. These factors ensure studies are fully recruited, and start and conclude on-time. Cetero also works with a large endocrinology physician practice, which provides Cetero and its clients with access to additional patients.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
